Skip to content
goodwin-final-color Color Goodwin logo
  • Manufacturing Solutions
    • Analytical Method Development
    • Clinical GMP Manufacturing Services
    • Upstream Development
    • Downstream Development
    • Aseptic Fill & Finish
    • Bioconjugation
  • Support Solutions
    • Regulatory & CMC Support
    • Quality Control
    • Quality Assurance
    • Project Management
    • Consulting Services
    • Cell Line Development
  • Applications
    • COVID-19
    • Exosomes
    • Biosimilars & Biobetters
    • Multispecific Antibodies & Antibody Fragments
  • About
    • Who We Are
    • Leadership
    • Board of Directors
    • Facilities and Location
    • Why Goodwin Biotechnology?
    • Goodwin Awards
    • Collaborations & Partnerships
    • News
      • Press Releases
      • Upcoming Events
      • In the News
      • Publications & Patents
    • Careers
  • Contact Us
  • Manufacturing Solutions
    • Analytical Method Development
    • Clinical GMP Manufacturing Services
    • Upstream Development
    • Downstream Development
    • Aseptic Fill & Finish
    • Bioconjugation
  • Support Solutions
    • Regulatory & CMC Support
    • Quality Control
    • Quality Assurance
    • Project Management
    • Consulting Services
    • Cell Line Development
  • Applications
    • COVID-19
    • Exosomes
    • Biosimilars & Biobetters
    • Multispecific Antibodies & Antibody Fragments
  • About
    • Who We Are
    • Leadership
    • Board of Directors
    • Facilities and Location
    • Why Goodwin Biotechnology?
    • Goodwin Awards
    • Collaborations & Partnerships
    • News
      • Press Releases
      • Upcoming Events
      • In the News
      • Publications & Patents
    • Careers
  • Contact Us

Press Releases

Who We Are / News / Press Releases

Goodwin Biotechnology Announces the Return of Two Important Monoclonal Antibody Projects from Alethia Biotherapeutics

  • October 1, 2013

Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer

  • September 1, 2013

Goodwin Biotechnology, Inc. Announces Process Development Sub-Contract for an Anthrax Vaccine

  • June 3, 2013

Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates

  • April 25, 2013

Goodwin Biotechnology Inc. Completes Development of AREVA’s New Cancer Treatment

  • December 12, 2012

Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards

  • October 1, 2012

Goodwin Biotechnology and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate that Potentially Represents a Critical Advance in Oncology

  • June 4, 2012

ImmunoSite Technologies Allies with Goodwin Biotechnology Increasing Capabilities

  • November 1, 2011

Goodwin Biotechnology Announces a Collaboration with Spectros Corporation

  • October 1, 2011

Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a “Bench-to-Clinic” Collaboration for an Important Advance in Oncology

  • January 1, 2011
Previous 1 2 3 4 5 Next

1850 N.W. 69th Avenue Plantation, FL 33313 USA 800-814-8600

  • Facebook
  • Twitter
  • LinkedIn
  • Manufacturing Solutions
    • Analytical Method Development
    • Clinical GMP Manufacturing Services
    • Upstream Development
    • Downstream Development
    • Aseptic Fill & Finish
    • Bioconjugation
  • Support Solutions
    • Regulatory & CMC Support
    • Quality Control
    • Quality Assurance
    • Project Management
    • Consulting Services
    • Cell Line Development
  • Applications
    • COVID-19
    • Exosomes
    • Biosimilars & Biobetters
    • Multispecific Antibodies & Antibody Fragments
  • Who We Are
    • Who We Are
    • Leadership
    • Board of Directors
    • Facilities & Location
    • Why Goodwin Biotechnology?
    • Goodwin Awards
    • Collaborations & Partnerships
    • News
    • Careers
© 2021 Goodwin Biotechnology Inc. All rights Reserved.
  • Privacy Policy
  • Sitemap